| __timestamp | Catalyst Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 17986000 |
| Thursday, January 1, 2015 | 8597010 | 32480000 |
| Friday, January 1, 2016 | 7910260 | 68081000 |
| Sunday, January 1, 2017 | 7304399 | 169906000 |
| Monday, January 1, 2018 | 15875961 | 248932000 |
| Tuesday, January 1, 2019 | 36881187 | 354100000 |
| Wednesday, January 1, 2020 | 44233754 | 433300000 |
| Friday, January 1, 2021 | 49628000 | 583300000 |
| Saturday, January 1, 2022 | 58183000 | 752700000 |
| Sunday, January 1, 2023 | 133710000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing the power of data
In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Neurocrine Biosciences saw a staggering 4,800% increase in SG&A expenses, peaking at nearly $888 million in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Catalyst Pharmaceuticals experienced a more moderate 2,900% rise, reaching approximately $134 million in the same year.
These trends highlight the differing growth trajectories and strategic priorities of the two companies. While Neurocrine's substantial increase suggests a focus on scaling operations, Catalyst's steadier rise indicates a more conservative approach. Understanding these dynamics offers valuable insights into the financial strategies driving success in the biotech sector.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Catalyst Pharmaceuticals, Inc.